Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
· Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing · Three million people in the US diagnosed with opioid use disorder Lund, Sweden — 23 May 2023 — Camurus (NASDAQ STO: CAMX) today announces that the US Food and Drug Administration (FDA) has approved Brixadi™ (buprenorphine) extended release injection for subcutaneous (SC) use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder (OUD), in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are